Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022

Horizon Therapeutics plc to Release First-Quarter 2022 Financial Results and Host Webcast on May 4, 2022

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Horizon Therapeutics (HZNP) Up 7.6% Since Last Earnings Report: Can It Continue?

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces new analysis finding UPLIZNA effective for people with newly-presenting neuromyelitis optica spectrum disorder (NMOSD).

New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been recognized as one of the Best Workplaces in Ireland 2022 by Great Place to Work Ireland, ranking No. 9 in the medium company category. “We are proud to be named to the Great Place to Work in Ireland list for the third consecutive year,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Ireland has been our home for almost a decade and has served as the foundation for our

Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland

The FDA grants priority review to Horizon's (HZNP) sBLA for Krystexxa plus methotrexate to treat people living with uncontrolled gout. A decision is due on Jul 7, 2022.

Horizon's (HZNP) sBLA for Krystexxa Gets FDA Priority Review

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) granted priority review of the supplemental Biologics License Application (sBLA) to expand the label for KRYSTEXXA plus methotrexate, an immunomodulator commonly prescribed by rheumatologists. The Prescription Drug User Fee Act (PDUFA) action date is July 7, 2022. KRYSTEXXA is indicated for the treatment of chronic gout in adult patients refractory to conventional th

Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living With Uncontrolled Gout

Horizon's (HZNP) revenues beat estimates in the fourth quarter of 2021. Shares rise following the results.

Horizon (HZNP) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

Horizon Therapeutics PLC (HZNP) CEO Tim Walbert on Q4 2021 Results - Earnings Call Transcript

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.02% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Beat Estimates

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Fourth-Quarter 2021 and Full-Year 2021 Financial Results; Announces Full-Year 2022 Guidance

Horizon Therapeutics plc Reports Fourth-Quarter 2021 and Full-Year 2021 Financial Results; Announces Full-Year 2022 Guidance

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of the #RAREis Representation program, which expands Horizon's #RAREis program to support advancing global equity in the rare disease community. The program is centered around a new section of the #RAREis website where individuals are invited to provide feedback via a short survey on key issues related to rare disease equity, which will be used to inform long-term programming, toolkits and resources for

Horizon Therapeutics plc Launches #RAREis Representation Program to Elevate Global Rare Disease Equity

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces the initiation of a Phase 3 trial (OPTIC-J) in Japan evaluating teprotumumab for the treatment of active TED.

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will present at the following conference in March: Cowen and Company 42nd Annual Health Care Conference (Virtual) Date: Tuesday, March 8, 2022 Presentation time: 11:10 a.m. ET The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of the webcast will be available following the event. About Horizon Horizon is focused on

Horizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference

Horizon Therapeutics plc (NASDAQ: HZNP) shared results from a new analysis showing treatment with Uplinza reduced the severity of attacks in people with Neuromyelitis Optica Spectrum Disorder (NMOSD).  The data will be presented at the 48th Annual Meeting of the North American Neuro-Ophthalmology Society.

Horizon Therapeutics' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today named Sean Clayton as executive vice president and general counsel effective Feb. 28. Sean will report directly to Tim Walbert, chairman, president and chief executive officer and will join the Company's executive committee. “Sean has been a trusted partner to Horizon for more than a decade in his role at Cooley and has a deep understanding of our current business and long-term strategy,” said Walbert. “That knowledge of our

Horizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc announced results from an analysis showing treatment with UPLIZNA effectively reduced the severity of attacks in NMOSD.

New Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results from a post-marketing safety analysis of TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease.

New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations

DEERFIELD, Ill.--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced a new partnership with nonprofits the Doug the Pug Foundation and Sing Me A Story Foundation through the company's #RAREis Playlist program, to amplify the voices of children with rare diseases through storytelling and song. According to the National Institutes of Health, a rare disease is any condition affecting fewer than 200,000 people, and of the about 7,000 known rare diseases, about 80% are genetic a

Horizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has been named the Title Partner of the Irish Open in a six-year deal, which will begin with the 2022 Horizon Irish Open at Mount Juliet Estate in County Kilkenny, Ireland, from June 30 to July 3. “Horizon has called Ireland home for nearly ten years and this partnership with the DP World Tour further solidifies our continued economic and community commitment,” said Tim Walbert, chairman, president and chief exe

Horizon Therapeutics plc Named Title Partner of the Irish Open

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2021 financial results on Tuesday, March 1, 2022. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the liv

Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022

Horizon generates giant revenues the old fashioned way, from clever acquisitions.

Horizon Therapeutics: Powerful Pharma Player On Long-Term Growth Track

Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.

Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2b pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with IPF, the most common interstitial lung disease. IPF is a rare, progressive lung disease caused by inflammation and fibrosis, or scarring, of the lungs. It is characterized by dyspnea, chronic cough and potentially death. There are a

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

AbbVie

Catalyst Pharmaceuticals

Innoviva

Eli Lilly

Pfizer

Zoetis

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appeared first on InvestorPlace.

7 of the Top-Rated Pharmaceutical Stocks for Q1

Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.

News for Horizon Pharma Stock (HZNP)